Broad Portfolio Expansion
North Star Asset Management Expands Portfolio With Multi-Million Dollar Stakes in Tech and Finance
Anonymous
Key Points
1
Zscaler’s stock is highly owned by institutions, with 46.45% of the float held by institutional investors and hedge funds, and the stock attracting a broad analyst consensus (34 Buy ratings, 6 Holds, 1 Sell) with multiple price targets, including KeyCorp at $210 and JPMorgan Chase at $215.
2
UBS Group AG increased its stake in Fidelity National Financial by 8.9% in the 4th quarter, bringing its total to 1,664,396 shares (valued at roughly $90.9 million), while Fidelity National Financial remains highly institutionally owned (about 81.17%).
3
North Star’s Repligen purchase consisted of 77,561 shares valued at about $10.58 million, and the stock also saw notable insider activity with CFO Jason K. Garland selling 733 shares on June 25.
4
CoStar Group highlights include IFP Advisors Inc boosting its stake by 329.4% in the 4th quarter, reflecting continued institutional rebalancing; overall, 96.60% of the stock is owned by institutional investors.
5
North Star’s new Schwab position amounts to 478,540 shares (about $44.16 million), but the company also saw its chairman, Walter W. Bettinger, sell 176,210 shares on August 24, reducing his stake by roughly 22.4%.
North Star Asset Management Inc. expanded its portfolio significantly in the second quarter, taking new or increased stakes across technology, financial services, and biotech companies. Watchlist News reported that the fund purchased 38,306 shares of Zscaler worth $5.4 million, while also investing over $9.5 million in Fidelity National Financial and roughly $10.6 million in Repligen — signaling a broad diversification strategy across multiple sectors.
New Bet on Zscaler Amid Heavy Institutional Interest
North Star's new position in Zscaler totaled 38,306 shares valued at approximately $5.4 million Watchlist News. The cybersecurity software company is heavily owned by institutions, with 46.45% of its float held by institutional investors and hedge funds. Analysts overwhelmingly favor the stock with 34 Buy ratings, 6 Holds, and just 1 Sell. Price targets range from $210 by KeyCorp to $215 by JPMorgan Chase, suggesting confidence in near-term upside.
Fidelity National Financial Attracts Institutional Capital
North Star purchased 244,297 shares of Fidelity National Financial for about $9.5 million Watchlist News, joining other major institutions in strengthening their positions. UBS Group AG significantly increased its stake by 8.9% in the fourth quarter, bringing its total to 1,664,396 shares worth roughly $90.9 million. Fidelity National Financial remains highly institutionally owned at approximately 81.17%, indicating strong institutional confidence in the financial services company.
Repligen Draws Multiple Institutional Investors
North Star's Repligen purchase comprised 77,561 shares valued at about $10.58 million Watchlist News, part of a wider institutional influx into the biotech stock. The investment coincided with insider activity, as CFO Jason K. Garland sold 733 shares on June 25, suggesting mixed sentiment among company leadership. The broad institutional participation underscores investor interest in the biotech sector despite mixed insider moves.
CoStar and Schwab Round Out Diversified Portfolio Shift
North Star added 112,073 shares of CoStar Group during the second quarter Watchlist News, joining other institutions in rebalancing their real estate data holdings. CoStar remains highly institutionally owned at 96.60%, while IFP Advisors Inc. boosted its position by 329.4% in the fourth quarter. North Star also acquired 478,540 shares of The Charles Schwab Corporation worth approximately $44.16 million, though Schwab's chairman Walter W. Bettinger sold 176,210 shares on August 24, reducing his stake by roughly 22.4%.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
19
Articles
34
Reach
53
Topics
A
AnonymousAuthor
